Novocure Ltd

NASDAQ NVCR

Data sourced from

and

Daily

Download Data

Novocure Ltd Price to Sales Ratio (P/S) on June 03, 2024: 4.89

Novocure Ltd Price to Sales Ratio (P/S) is 4.89 on June 03, 2024, a -70.69% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Novocure Ltd 52-week high Price to Sales Ratio (P/S) is 16.69 on June 05, 2023, which is 241.20% above the current Price to Sales Ratio (P/S).
Novocure Ltd 52-week low Price to Sales Ratio (P/S) is 2.36 on November 10, 2023, which is -51.79% below the current Price to Sales Ratio (P/S).
Novocure Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 4.30.

NASDAQ: NVCR

Novocure Ltd

CEO	Mr. William F. Doyle
IPO Date	Oct. 2, 2015
Location	Jersey
Headquarters	No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees	1,453
Sector	Healthcare
Industry	Medical devices

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends